Biomarker ID | 542 |
PMID | 20889560 |
Year | 2010 |
Biomarker | MMP-9 intensity |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | Increased expression in Overall Mortality |
Odds Ratio/Hazard Ratio/Relative Risk | Univariate Analysis: HR: 0.6 (95% CI: 0.45-0.8) |
Effect on Pathways | Pathway Includes:- Syndecan 1 pathway,Gastrin pathway,Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling,TWEAK signaling pathway, Endochondral ossification |
Experiment | Overall Mortality Vs No Mortality |
Type of Biomarker | Prognostic |
Cohort | 278 with prostate cancer were chosen. At the end time, 210 patients were alive, 228 patients had no event with regard to disease-specific mortality, and 87 patients were without biochemical recurrence were chosen. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.001 |
Method Used | Immunohistochemistry |
Clinical | No |
Remarks | This study stands in contrast to other studies, showing an association of MMP-9 expression with tumor progression in PCa |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | MMP9 |